Advances in pharmacotherapy for primary biliary cholangitis / 临床肝胆病杂志
Journal of Clinical Hepatology
;
(12): 1188-1191, 2017.
Article
Dans Chinois
| WPRIM
| ID: wpr-613347
ABSTRACT
The pathogenesis of primary biliary cholangitis (PBC) remains unclear.Ursodeoxycholic acid (UDCA) is currently the only drug approved by the Food and Drag Administration for the treatment of PBC,but some patients have a poor response to UDCA.New therapies can be considered for these patients.This article reviews the advances in drugs for PBC,including 6or-ethyl-chenodeoxycholic acid,fibrates,budesonide,and biological agents,and points out that these drugs bring new hope for PBC patients,but large-scale clinical studies are needed to confirm the long-term efficacy and safety.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Journal of Clinical Hepatology
Année:
2017
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS